Get started
Work

257P Phase I clinical trial of ragistomig (ABL503/TJ-L14B: PD-L1 × 4-1BB bispecific antibody) Q6W dosing balances favorable safety and sustained efficacy through extended immunologic memory and reinvigoration of CD8+ T cells

Year: 2025
Type: article
Abstract: 4-1BB(CD137), a costimulatory receptor of TNFR superfamily, enhances T-cell proliferation and memory function. First-generation 4-1BB agonist antibodies were limited by hepatotoxicity. Bispecific antibodies targeting PD-L1 and 4-1BB have been developed to restrict costimulation of 4-1BB only at PD-L1 expressing tumor sites, thereby reducing systemic toxicity while maintaining anti-tumor activity. Preliminary results from the phase 1 trial of ragistomig (ABL503/TJ-L14B) showed encouraging clinical activity with manageable toxicity.
DOI: 10.1016/j.iotech.2025.101456
Authors: G.S. Falchook, A.B. El-Khoueiry, J. Thomas, A.W. Tolcher, J. Henry, A.I. Spira, D. Yardley, A. Philipovskiy, J.W. Goldman, B. Keam, T-Y. Kim, H.R. Kim, D.H. Lee, Y.W. Moon, K.H. Park, C. Xu, P.A. Dennis, S. Lee, J. Jeon, E.B. Garon
Institutions: HealthONE, University of Southern California, USC Norris Comprehensive Cancer Center, Virginia Cancer Specialists, Tennessee Oncology, Florida Cancer Specialists & Research Institute, University of California, Los Angeles, Seoul National University, Seoul National University Hospital, Yonsei University, Yonsei Cancer Hospital, Asan Medical Center, University of Ulsan, CHA University Bundang Medical Center, CHA University, Korea University Anam Hospital, ABL Bio (South Korea)
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,340
OpenAlex ID: W7117333376
FWCI:
Cites:
Cited by:
Related to: